Navigation Links
Sugammadex Study First to Show Rapid Reversal of Profound Rocuronium-Induced Muscle Relaxation is Possible
Date:10/28/2008

return of the train-of-four (TOF) ratio to 0.9. Profound neuromuscular blockade reversal with sugammadex 4 mg/kg was about 17 times faster than with neostigmine 70 mcg/kg (geometric mean times were 2.9 minutes versus 50.4 minutes, respectively [P<0.0001], while median times were 2.7 minutes versus 49.0 minutes). In the study, 97 percent of sugammadex-treated patients recovered to a TOF ratio of 0.9 within five minutes of administration. In contrast, 73 percent of neostigmine-treated patients did not recover until 30-60 minutes, and a large proportion (23 percent) did not recover to a TOF ratio of 0.9 until more than 60 minutes after neostigmine administration.

The study enrolled surgical patients, aged 18 years or older with American Society of Anesthesiology physical status I-IV. Seventy-four patients were randomized to receive sugammadex (4.0 mg/kg) or neostigmine (70 mcg/kg) plus glycopyrrolate (14 mcg/kg) and completed the study. Anesthetized patients received an intubating dose of rocuronium (0.6 mg/kg), with maintenance doses (0.15 mg/kg) as required. Neuromuscular monitoring was performed by acceleromyography.

In the study, sugammadex was well tolerated in the 37 patients who received the treatment, and its safety profile overall was comparable with that of neostigmine. Safety data from the study showed that the most frequently reported adverse events (AEs) for patients in both groups included procedural pain, nausea and incision-site complications. Serious adverse events (SAEs) were reported for two patients in the sugammadex group (postoperative infection and postoperative ileus) and three patients in the neostigmine group (nausea/pain/dyspnea, gastric perforation/procedural complication and postoperative ileus). No SAE was considered study drug-related. Only one patient (neostigmine group) discontinued from the study because of two SAEs (gastric perforation/procedural complication) and subsequently recovered. No cases of hypersensitivity w
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. New Study Highlights Need for Better Interaction and Education Between Rheumatoid Arthritis Patients and Care Providers
2. QLT announces encouraging Phase II data from core study of Punctal Plug Drug Delivery System
3. Psychological study reveals that red enhances mens attraction to women
4. Study reveals factors of exceptional health in old age
5. Eating whole grains lowers heart failure risk, according to new study
6. Bloomberg School of Public Health to lead nationwide aging study
7. Latest Pistachio Study Reveals Significant Reduction in Markers of Inflammation - an Emerging Risk Factor in Heart Disease
8. University of Illinois - Chicago Study: Raisins Contain Compounds that May Inhibit Cavity-causing Bacteria
9. Study Reveals Factors of Exceptional Health in Old Age
10. AUDIO from Medialink and Genzyme: Study in New England Journal of Medicine Shows Investigational Compound Reduced Relapses and Disability in Patients With MS
11. Study finds that practice makes perfect in lung cancer surgery
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:New Research Shows a Vitamin/Nutriceutical Formulation Improves Memory and Cognitive Performance in Community-Dwelling Adults 2Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine 2Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine 3Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine 4Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine 5Multiple Sclerosis Patient Finds Hope Through Stem Cell Treatment 2Robin Leedy 26amp 3B Associates Wins Social Media Program For Union Springs Pharmaceuticals 55293 1Robin Leedy 26amp 3B Associates Wins Social Media Program For Union Springs Pharmaceuticals 55293 2A Place for Mom Announces Support in Effort to End Alzheimer 26apos 3Bs Disease 55291 1A Place for Mom Announces Support in Effort to End Alzheimer 26apos 3Bs Disease 55291 2Greenway Medical Technologies PrimeEnterprise Creates an Interconnected and Interoperable System of Community Health Information for Its Customers 55289 1Greenway Medical Technologies PrimeEnterprise Creates an Interconnected and Interoperable System of Community Health Information for Its Customers 55289 2Greenway Medical Technologies PrimeEnterprise Creates an Interconnected and Interoperable System of Community Health Information for Its Customers 55289 3